Semler Scientific (SMLR) has received a new Buy rating, initiated by Benchmark Co. analyst, Mark Palmer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mark Palmer has given his Buy rating due to a combination of factors influencing Semler Scientific’s strategic direction and market potential. The company’s recent pivot from a healthcare-focused business to adopting Bitcoin as its primary treasury reserve asset has been a significant driver of its stock appreciation. Despite this strategic shift, Semler Scientific’s valuation still lags behind its peers, presenting an opportunity for growth as it seeks to narrow the gap.
Furthermore, the company’s ambitious goals for expanding its Bitcoin treasury, alongside the appointment of a Director of Bitcoin Strategy, underscore its commitment to enhancing execution and investor engagement. Additionally, resolving challenges in its legacy healthcare business, such as the DOJ investigation and Medicare reimbursement issues, could further bolster its valuation. Mark Palmer’s price target of $101 reflects a sum-of-the-parts analysis, considering both the potential appreciation of Bitcoin and the value of Semler Scientific’s healthcare operations.